Coptisine exerts anti‐tumour effects in triple‐negative breast cancer by targeting mitochondrial complex I

This is the authors' abstract. We don't add key points for this paper.

Triple-negative breast cancer (TNBC) has a poor prognosis due to limited therapeutic options. Recent studies have shown that TNBC is highly dependent on mitochondrial oxidative phosphorylation. The aim of this study was to investigate the potential of coptisine, a novel compound that inhibits the complex I of the mitochondrial electron transport chain (ETC), as a treatment for TNBC.